• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

HDAC-IN-4

CAS No. 934828-12-3

HDAC-IN-4 ( AZD 9468 )

产品货号. M16687 CAS No. 934828-12-3

组蛋白脱乙酰酶 (HDAC) 抑制剂。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
5MG ¥1021 有现货
10MG ¥1604 有现货
25MG ¥3281 有现货
50MG ¥4836 有现货
100MG ¥6901 有现货
200MG 获取报价 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    HDAC-IN-4
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    组蛋白脱乙酰酶 (HDAC) 抑制剂。
  • 产品描述
    A histone deacetylase (HDAC) inhibitor, extracted from patent WO/2007045844 A1.(In Vitro):Zabadinostat has been tested in vitro in colon, lung, non-Hodgkin lymphoma, and myeloma cell lines with IC50s ranged from 0.2 to 15 μM.(In Vivo):Zabadinostat substantially reduces tumor size in murine xenograft lung (A549a) and colon (HT29) models at a dose of 50 mg/kg. Tumor reductions are found to be associated with increased histone acetylation and decreased HDAC enzyme activity.For Zabadinostat, after oral dosing in murine and canine models, peak plasma concentrations (Cmax) are reached 1 to 2 hours after the dose and terminal half‐lives are 6 hours and 8 hours, respectively. After murine oral [14C]-Zabadinostat at a dose of 1.6 mg/kg (4 μmol/kg), tissue radioactivity peaked 3 to 6 hours after the dose and declined slowly thereafter with Zabadinostat‐related material still present in tissue 21 days after the dose.
  • 体外实验
    Zabadinostat has been tested in vitro in colon, lung, non-Hodgkin lymphoma, and myeloma cell lines with IC50s ranged from 0.2 to 15 μM.
  • 体内实验
    Zabadinostat substantially reduces tumor size in murine xenograft lung (A549a) and colon (HT29) models at a dose of 50 mg/kg. Tumor reductions are found to be associated with increased histone acetylation and decreased HDAC enzyme activity.For Zabadinostat, after oral dosing in murine and canine models, peak plasma concentrations (Cmax) are reached 1 to 2 hours after the dose and terminal half‐lives are 6 hours and 8 hours, respectively. After murine oral [14C]-Zabadinostat at a dose of 1.6 mg/kg (4 μmol/kg), tissue radioactivity peaked 3 to 6 hours after the dose and declined slowly thereafter with Zabadinostat‐related material still present in tissue 21 days after the dose.
  • 同义词
    AZD 9468
  • 通路
    Cell Cycle/DNA Damage
  • 靶点
    HDAC
  • 受体
    HDAC
  • 研究领域
    Cancer
  • 适应症
    ——

化学信息

  • CAS Number
    934828-12-3
  • 分子量
    403.52
  • 分子式
    C24H29N5O
  • 纯度
    >98% (HPLC)
  • 溶解度
    DMSO: ≥ 31 mg/mL
  • SMILES
    O=C(NC1=CC=CC=C1N)C2=CC=C(C3CCN(CC4=CN(C)N=C4C)CC3)C=C2
  • 化学全称
    Benzamide, N-(2-aminophenyl)-4-[1-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]-4-piperidinyl]-

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1. PCT Int. Appl. (2007), WO 2007045844 A1 20070426.
产品手册
关联产品
  • YPX-C-05

    YPX-C-05 是一种基于异羟肟酸的 HDAC 抑制剂。YPX-C-05 具有显着的血管舒张作用。YPX-C-05 对 HDAC 表现出抑制作用,并增加内皮细胞中的组蛋白 H4 乙酰化。YPX-C-05 可用于高血压研究。

  • NCC-149

    一种有效的选择性 HDAC8 抑制剂,IC50 为 70 nM。

  • FT895

    FT895 (FT-895) 是一种有效的选择性 HDAC11 抑制剂,IC50 为 3 nM。